Acadia Pharmaceuticals (ACAD) EBITDA Margin (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly EBITDA Margin of 1.72% for Q1 2026, down 962.0% year-over-year from 0.2% in Q1 2025, and down 128.12% quarter-over-quarter from 6.12% in Q4 2025.
Powered by 
Analysis
Acadia Pharmaceuticals (ACAD) EBITDA Margin (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' EBITDA Margin history runs 17 years deep, the most recent figure standing at 1.72% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 962.0% year-over-year to 1.72%; the TTM figure through Mar 2026 stood at 7.39% (down 1619.0% YoY), while the FY2025 annual figure was 9.78%, down 1431.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 1.72%, down from 6.12% in the prior quarter.
- The five-year high for EBITDA Margin was 59.13% in Q4 2024, with the low at 97.88% in Q1 2022.
- The 5-year median for EBITDA Margin is 6.12% (2025), against an average of 6.28%.
- The sharpest annual moves came in 2023 and 2025: EBITDA Margin surged 5264 bps in 2023, then sank 5301 bps in 2025.
- Acadia Pharmaceuticals' EBITDA Margin stood at 33.75% in 2022, then jumped by 145 bps to 15.12% in 2023, then surged by 291 bps to 59.13% in 2024, then sank by 90 bps to 6.12% in 2025, then sank by 128 bps to 1.72% in 2026.
- Business Quant data shows ACAD's EBITDA Margin at 1.72% in Q1 2026, 6.12% in Q4 2025, and 12.83% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Acadia Pharmaceuticals | 4.82 Bn | 3.86 Bn | 279.64 Mn | 12.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.29% |
| Mar 31, 2026 | -1.72% |
| Dec 31, 2025 | 6.12% |
| Sep 30, 2025 | 12.83% |
| Jun 30, 2025 | 12.24% |
| Mar 31, 2025 | 7.90% |
| Dec 31, 2024 | 59.13% |
| Sep 30, 2024 | 12.64% |
| Jun 30, 2024 | 12.58% |
| Mar 31, 2024 | 7.39% |
| Dec 31, 2023 | 15.12% |
| Sep 30, 2023 | -27.29% |
| Jun 30, 2023 | 1.84% |
| Mar 31, 2023 | -45.23% |
| Dec 31, 2022 | -33.75% |
| Sep 30, 2022 | -23.61% |
| Jun 30, 2022 | -25.01% |
| Mar 31, 2022 | -97.88% |
| Dec 31, 2021 | -34.15% |
| Sep 30, 2021 | -11.63% |